Our Team

Nathan D. Trinklein, Ph.D.

Nathan is a co-founder and the CEO of SwitchGear Genomics. In addition to managing SwitchGear’s business development efforts, Nathan oversees research projects and collaborations related to technology development, bioinformatics, and applications in the area of regulatory network and pathway analysis. Before founding SwitchGear, he managed the Stanford ENCODE Project and has over 12 years of experience and publications in the field of functional genomics. Nathan received his Ph.D. from the Genetics Department at Stanford University.

Shelley Force Aldred, Ph.D.

Shelley is a co-founder and the President of SwitchGear Genomics. She manages the corporate structure, company finances, and investor relations. Shelley also oversees research projects, large collaborations, and partnerships related to studies of regulatory element sequence variation and human genetics. She has over 12 years of experience and publications in the field of large-scale regulatory element analysis and the effects of promoter variants in human disease. She received her Ph.D. from the Genetics Department at Stanford University as a Geraldine Jackson Fuhrman Graduate Fellow.


Jim Hudson

Jim played an integral role in the Human Genome Project and is a well-respected member of the Genomics community. He is the founder and president of Research Genetics, a genomics reagent company in Huntsville, Alabama, that was acquired by Invitrogen in 1999 for $140M. He is also a founding board member of Shearwater Polymers and New Century Pharmaceuticals. Jim has recently co-founded the Hudson-Alpha Institute for Biotechnology, a large medical research institute in Huntsville, Alabama.

Andrew Farquharson

Andrew Farquharson is an early-stage investor in life sciences, who brings 14 years of experience as a founder, executive and researcher in the biotherapeutic, genomic and proteomic arenas. He is a Kauffman Fellow and Chairman of Ergodesigns, Inc., which he founded in 2003. Mr. Farquharson served as Senior Vice President of sales and marketing for QIAGEN Operon, where he tripled revenues of synthetic DNA products in two years, and played a key role in negotiating a sale of the business for nine figures. Mr. Farquharson received a BA with High Honors from the University of California at Berkeley, and his Masters of Business Administration from Harvard University Graduate School of Business.

Deval Lashkari

Deval has worked in the life sciences area over the past 18 years developing and commercializing novel technologies. He gained corporate and business development experience through senior management founding Research Director at Synteni, which was acquired by Incyte Genomics, where he was Director of Product Development. He also worked with Operon Technologies, acquired by Qiagen, and Genometrix. He is currently a director of AcroMetrix, Althea Technologies, Applied Precision and Aurora Discovery. Deval received a BA from the University of California, Berkeley and a Ph.D. from Stanford University.

Jack Ball

Jack has a proven record of bringing life science products to market and capitalizing on existing product potential. Most recently he was Chief Commercial Officer at Accuri Cytometers where he developed a novel commercialization model that is highly capital efficient. He and the management team sold the company to Becton Dickinson for $205M in March 2011. Prior to Accuri Cytometers, he was CEO of Amnis Corporation, a venture backed technology start-up developing and selling high-end imaging flow cytometers. He has also served as Chief Commercial Officer for Molecular Probes, Inc., the world leader in reagents for cell analysis. Prior to that he was with Orchid Biosciences as General Manager and with Amersham Pharmacia Biotech Inc., where he rose to President, Region North America.

Nathan D. Trinklein

Shelley Force Aldred


Richard M. Myers, Ph.D.

Rick is a co-founder of SwitchGear Genomics and currently serves as the chairman of the SAB. He has been an established leader in the field of gene regulation and the genetics of human disease for 25 years. Rick is currently the Director of the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. Prior to joining HudsonAlpha, Rick was the Chairman of the Genetics Department at Stanford University and Director of the Stanford Human Genome Research Institute.

James M. Ford, M.D.

Jim currently serves as a member of the SAB of SwitchGear Genomics. He is currently a professor at Stanford University in the Departments of Genetics and Medical Oncology. Jim is an established leader in the field of DNA damage, cancer, and translational medicine. He discovered that the p53 and BRCA1 tumor suppressor genes regulate DNA repair, and has developed novel assays to examine DNA repair activity in primary human tissues. He is developing techniques for high-throughput genomic analyses of cancer to identify molecular signatures for targeted therapies.